Your browser does not allow JavaScript!
JavaScript is necessary for the proper functioning of this website. Please enable JavaScript or use a modern browser.
Open Science Slovenia
Open Science
DiKUL
slv
|
eng
Search
Browse
New in RUL
About RUL
In numbers
Help
Sign in
Meta-analysis and experimental validation identified FREM2 and SPRY1 as new glioblastoma marker candidates
ID
Vidak, Marko
(
Author
),
ID
Jovchevska, Ivana
(
Author
),
ID
Šamec, Neja
(
Author
),
ID
Zottel, Alja
(
Author
),
ID
Liović, Mirjana
(
Author
),
ID
Rozman, Damjana
(
Author
),
ID
Džeroski, Sašo
(
Author
),
ID
Juvan, Peter
(
Author
),
ID
Komel, Radovan
(
Author
)
PDF - Presentation file,
Download
(9,34 MB)
MD5: 83FE430F48BFB92CCC15C1E10F308C74
URL - Source URL, Visit
http://www.mdpi.com/1422-0067/19/5/1369
Image galllery
Abstract
Glioblastoma (GB) is the most aggressive brain malignancy. Although some potential glioblastoma biomarkers have already been identified, there is a lack of cell membrane-bound biomarkers capable of distinguishing brain tissue from glioblastoma and/or glioblastoma stem cells (GSC), which are responsible for the rapid post-operative tumor reoccurrence. In order to find new GB/GSC marker candidates that would be cell surface proteins (CSP), we have performed meta-analysis of genome-scale mRNA expression data from three data repositories (GEO, ArrayExpress and GLIOMASdb). The search yielded ten appropriate datasets, and three (GSE4290/GDS1962, GSE23806/GDS3885, and GLIOMASdb) were used for selection of new GB/GSC marker candidates, while the other seven (GSE4412/GDS1975, GSE4412/GDS1976, E-GEOD-52009, E-GEOD-68848, E-GEOD-16011, E-GEOD-4536, and E-GEOD-74571) were used for bioinformatic validation. The selection identified four new CSP-encoding candidate genes-CD276, FREM2, SPRY1, and SLC47A1-and the bioinformatic validation confirmed these findings. A review of the literature revealed that CD276 is not a novel candidate, while SLC47A1 had lower validation test scores than the other new candidates and was therefore not considered for experimental validation. This validation revealed that the expression of FREM2-but not SPRY1-is higher in glioblastoma cell lines when compared to non-malignant astrocytes. In addition, FREM2 gene and protein expression levels are higher in GB stem-like cell lines than in conventional glioblastoma cell lines. FREM2 is thus proposed as a novel GB biomarker and a putative biomarker of glioblastoma stem cells. Both FREM2 and SPRY1 are expressed on the surface of the GB cells, while SPRY1 alone was found overexpressed in the cytosol of non-malignant astrocytes.
Language:
English
Keywords:
glioblastoma
,
glioblastoma stem cells
,
biomarkers
,
data repositories
,
meta-analysis
,
cell surface
,
experimental validation
,
FREM2
,
SPRY1
Work type:
Article
Typology:
1.01 - Original Scientific Article
Organization:
MF - Faculty of Medicine
Publication status:
Published
Publication version:
Version of Record
Year:
2018
Number of pages:
24 str.
Numbering:
Vol. 19, iss. 5, art. 1369
PID:
20.500.12556/RUL-131851
UDC:
577
ISSN on article:
1422-0067
DOI:
10.3390/ijms19051369
COBISS.SI-ID:
33752793
Publication date in RUL:
04.10.2021
Views:
1273
Downloads:
196
Metadata:
Cite this work
Plain text
BibTeX
EndNote XML
EndNote/Refer
RIS
ABNT
ACM Ref
AMA
APA
Chicago 17th Author-Date
Harvard
IEEE
ISO 690
MLA
Vancouver
:
Copy citation
Share:
Record is a part of a journal
Title:
International journal of molecular sciences
Shortened title:
Int. j. mol. sci.
Publisher:
MDPI
ISSN:
1422-0067
COBISS.SI-ID:
2779162
Licences
License:
CC BY 4.0, Creative Commons Attribution 4.0 International
Link:
http://creativecommons.org/licenses/by/4.0/
Description:
This is the standard Creative Commons license that gives others maximum freedom to do what they want with the work as long as they credit the author.
Licensing start date:
04.05.2018
Secondary language
Language:
Slovenian
Keywords:
glioblastom
,
matične celice glioblastoma
,
biomarkerji
Projects
Funder:
Other - Other funder or multiple funders
Funding programme:
Junior Researcher grant
Project number:
1240-1/2013-123-2
Funder:
ARRS - Slovenian Research Agency
Project number:
P1-0390
Name:
Funkcijska genomika in biotehnologija za zdravje
Funder:
ARRS - Slovenian Research Agency
Project number:
P2-0103
Name:
Tehnologije znanja
Funder:
EC - European Commission
Funding programme:
Interreg
Acronym:
TRANS-GLIOMA
Similar documents
Similar works from RUL:
Similar works from other Slovenian collections:
Back